WO2009099716A4 - Novel vaccines against multiple subtypes of dengue virus - Google Patents

Novel vaccines against multiple subtypes of dengue virus Download PDF

Info

Publication number
WO2009099716A4
WO2009099716A4 PCT/US2009/030776 US2009030776W WO2009099716A4 WO 2009099716 A4 WO2009099716 A4 WO 2009099716A4 US 2009030776 W US2009030776 W US 2009030776W WO 2009099716 A4 WO2009099716 A4 WO 2009099716A4
Authority
WO
WIPO (PCT)
Prior art keywords
dna plasmid
subtype
dengue virus
consensus
sequence
Prior art date
Application number
PCT/US2009/030776
Other languages
French (fr)
Other versions
WO2009099716A1 (en
WO2009099716A9 (en
Inventor
Mathura P. Ramanathan
Niranjan Y. Sardesal
Original Assignee
Vgx Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2708668A priority Critical patent/CA2708668C/en
Application filed by Vgx Pharmaceuticals, Inc. filed Critical Vgx Pharmaceuticals, Inc.
Priority to ES09707528.7T priority patent/ES2685435T3/en
Priority to EP09707528.7A priority patent/EP2234624B1/en
Priority to CN200980101862.0A priority patent/CN101909635B/en
Priority to KR1020107017763A priority patent/KR101686942B1/en
Priority to JP2010542412A priority patent/JP5788676B2/en
Priority to US12/812,268 priority patent/US8835620B2/en
Priority to AU2009210624A priority patent/AU2009210624A1/en
Priority to MX2010007461A priority patent/MX2010007461A/en
Publication of WO2009099716A1 publication Critical patent/WO2009099716A1/en
Publication of WO2009099716A9 publication Critical patent/WO2009099716A9/en
Publication of WO2009099716A4 publication Critical patent/WO2009099716A4/en
Priority to ZA2010/04688A priority patent/ZA201004688B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.

Claims

AMENDED CLAIMS received by the International Bureau on 03 September 2009 (03.09.2009)
What is claimed:
1. A nucleic acid construct capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of Dengue virus, comprising: an encoding nucleotide sequence that expresses the polypeptide, wherein the polypeptide includes a Dm domain from at least two different Dengue virus subtypes, a promoter that regulates expression of the polypeptide in the mammal and is operably linked to the encoding nucleotide sequence.
2. The nucleic acid construct of claim 1, further comprising an IgE leader sequence operatively linked to an N-terminal end of the coding sequence and operably linked to the promoter.
3. The nucleic acid construct of any one of claims 1-2, further comprising a polyadenylation sequence attached to the C-termiπal end of the coding sequence.
4. The nucleic acid construct of claim 3, wherein the nucleic acid construct is codon optimized.
5. The nucleic acid construct of claim 4, wherein the encoding nucleotide sequence encodes a polypeptide that includes a DUI domain from dengue virus-subtype 1, dengue virus-subtype 2, dengue virus-subtype 3, or dengue virus-subtype 4, or a combination thereof.
6. The nucleic acid construct of claim 5, wherein the encoding nucleotide sequence is selected from the group consisting of SEQ ID NO: I, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.
7. A DNA plasmid vaccine capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising: a DNA plasmid capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, the consensus udengue antigen comprising consensus Dili domain of dengue virus-subtype I, dengue virus- subtype 2, dengue virus-subtype 3, or dengue virus-subtype 4, or a combination thereof, and a pharmaceutically acceptable excipient; the DNA plasmid comprising a promoter operably linked to a coding sequence that encodes the consensus dengue antigen.
8. The DNA plasmid vaccine of claim 7, wherein the DNA plasmid further comprises an IgE leader sequence attached to an N-terminal end of the coding sequence and operably Linked to the promoter.
9. The DNA plasmid vaccine of any one of claims 7-8, wherein the DNA plasmid further comprises a polyadenylation sequence attached to the C-terminal end of the coding sequence.
10. The DNA plasmid vaccine of claim 9, wherein the DNA plasmid is codon optimized.
11. The DNA plasmid vaccine of claim 10, wherein the pharmaceutically acceptable excipient is an adjuvant
12. The DNA plasmid vaccine of claim 11, wherein the adjuvant is selected from the group consisting of: IL- 12 and IL-15.
13. The DNA plasmid vaccine of claim 10, wherein the pharmaceutically acceptable excipient is a transfectioπ facilitating agent.
14. The DNA plasmid vaccine of claim 13, wherein the transfection facilitating agent is a polyanion, polycation, or lipid.
15. The DNA plasmid vaccine of claim 13, wherein the transfection facilitating agent is poly-L- glutamate at a concentration less than 6 mg/ml.
16. The DNA plasmid vaccine of claim 10, wherein the DNA plasmid vaccine has a concentration of total DNA plasmid of 1 mg/ml or greater.
17. The DNA plasmid vaccine of claim 16, wherein the DNA plasmid comprises a plurality of unique DNA plasmids, wherein each of the plurality of unique DNA plasmids encodes a polypeptide comprising a Dili domain from dengue virus-subtype 1, dengue vims-subtype 2, dengue virus-subtype 3, oi dengue virus-subtype 4, or a combination thereof.
18. The DNA plasmid vaccine of claim 17, wherein the encoding nucleotide sequence comprises SEQ ID NO; 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
19. The DNA plasmid vaccine of claim 17, comprising at least two different DNA plasmids that express a Dengue virus Dili domain, the plasmids selected from the group consisting of: a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 1 Din domain, a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 2 Dili domain, a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 3 Dili domain, and a DNA plβsmid comprising a sequence that encodes a consensus dengue virus-subtype 4 Dili domain.
0. The DNA plasmid vaccine of claim 19, comprising: the DNA plasmid comprising a sequence that encodes a consensus dengue virus -subtype
1 Dili domain, the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype
2 Dm domain, the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype
3 Dm domain, and the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype
4 Dili domain,
21. The DNA plasmid vaccine of claim 19, wherein the consensus dengue virus-subtype 1 DJH domain is SEQ ID NO: 1.
22. The DNA plasmid vaccine of claim 19, wherein the consensus dengue virus-subtype 2 Dili domain is SEQ ID NO: 2.
23. The DNA plasmid vaccine of claim 19, wherein the consensus dengue virus-subtype 3 Dili domain is SEQ ID NO: 3.
24. The DNA plasmid vaccine of claim 19, wherein the consensus dengue virus-subtype 4 Dili domain is SEQ ID NO: 4.
25. The DNA plasmid vaccine of claim 19, wherein the mammal is a nonhuman primate.
26. The DNA plasmid vaccine of claim 19, wherein the immune response is a humoral response.
27. The DNA plasmid vaccine of claim 19, wherein the immune response is a cellular response.
28. The DNA plasmid vaccine of claim 19, wherein the immune response is a combined humoral response and cellular response.
29. A method of eliciting an immune response against a plurality of subtypes of a virus in a mammal, comprising, delivering a DNA plasmid vaccine to tissue of the mammal, the DNA plasmid vaccine comprising a DNA plasmid capable of expressing a plurality of consensus antigens derived from the subtypes of the virus in a cell of the mammal to elicit an immune response in the mammal, the plurality of consensus antigens comprising an antigenic domain from at least two different subtypes of the virus, and electroporatiπg cells of the tissue with a pulse of energy at a constant current effective to permit entry of the DNA plasmids into the cells.
30. The method of claim 29, wherein the virus comprises west nile virus, human ' immunodeficiency virus, influenza virus, or dengue virus.
31. The method of any one of claims 29-30, wherein the delivering step comprises: injecting the DNA plasmid vaccine into intradermic, subcutaneous or muscle tissue.
32. The method of claim 31, further comprising: presetting a current that is desired to be delivered to the tissue; and electroporating cells of the tissue with a pulse of energy at a constant current that equals the preset current
33. The method of claim 32, wherein the electroporating step further comprises: measuring the impedance in the electroporated cells; adjusting energy level of the pulse of energy relative to the measured impedance to maintain a constant current in the electroporated cells; wherein the measuring and adjusting steps occur within a lifetime of the pulse of energy.
34. The method of claim 33, -wherein the electroporating step comprises: delivering the pulse of energy to a plurality of electrodes according to a pulse sequence pattern that delivers the pulse of energy in a decentralized pattern.
Figure imgf000009_0001
PCT/US2009/030776 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus WO2009099716A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2010542412A JP5788676B2 (en) 2008-01-11 2009-01-12 New vaccine against multiple subtypes of dengue virus
ES09707528.7T ES2685435T3 (en) 2008-01-11 2009-01-12 New vaccines against multiple subtypes of dengue virus
EP09707528.7A EP2234624B1 (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus
CN200980101862.0A CN101909635B (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus
KR1020107017763A KR101686942B1 (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus
CA2708668A CA2708668C (en) 2008-01-11 2009-01-12 Vaccines against multiple subtypes of dengue virus
US12/812,268 US8835620B2 (en) 2008-01-11 2009-01-12 Vaccines against multiple subtypes of dengue virus
AU2009210624A AU2009210624A1 (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus
MX2010007461A MX2010007461A (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus.
ZA2010/04688A ZA201004688B (en) 2008-01-11 2010-07-02 Novel vaccines against multiple subtypes of dengue virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2049008P 2008-01-11 2008-01-11
US61/020,490 2008-01-11

Publications (3)

Publication Number Publication Date
WO2009099716A1 WO2009099716A1 (en) 2009-08-13
WO2009099716A9 WO2009099716A9 (en) 2009-10-01
WO2009099716A4 true WO2009099716A4 (en) 2009-11-19

Family

ID=40952413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030776 WO2009099716A1 (en) 2008-01-11 2009-01-12 Novel vaccines against multiple subtypes of dengue virus

Country Status (11)

Country Link
US (1) US8835620B2 (en)
EP (1) EP2234624B1 (en)
JP (1) JP5788676B2 (en)
KR (1) KR101686942B1 (en)
CN (1) CN101909635B (en)
AU (1) AU2009210624A1 (en)
CA (1) CA2708668C (en)
ES (1) ES2685435T3 (en)
MX (1) MX2010007461A (en)
WO (1) WO2009099716A1 (en)
ZA (1) ZA201004688B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426827B1 (en) * 2006-11-06 2019-10-01 Microvax, Llc Dengue hemorrhagic fever virus vaccine
BRPI0904020B8 (en) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz vaccine composition against the dengue virus, and kit
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
CA2798331C (en) * 2010-05-14 2022-03-15 Baxter International Inc. Ospa chimeras and use thereof in vaccines
MX2012012681A (en) 2010-05-21 2012-12-17 Univ Pittsburgh Universal dengue virus sequences and methods of use.
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
EP2621525A4 (en) * 2010-10-01 2015-01-14 Univ Rochester Flavivirus domain iii vaccine
EP3760227A1 (en) 2011-02-11 2021-01-06 The Trustees of the University of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
JP6567824B2 (en) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and method of use thereof
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CA2898522A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
AU2014228497B2 (en) * 2013-03-15 2017-03-02 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
JP6457481B2 (en) * 2013-03-15 2019-01-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア New vaccine against multiple subtypes of dengue virus
ITRM20130458A1 (en) * 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And ANTI-DENGUE VIRUS GENETIC VACCINE BASED ON THE ECTODOMINS OF THE PROTEIN ENVELOPE
NO340722B1 (en) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgenic plants expressing a recombinant tetravalent chimeric dengue virus antigen to produce effective vaccines derived therefrom, as well as transgenic plastid, plant cell and seeds, recombinant DNA molecule, vector, methods of preparation and use thereof
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
WO2017142831A1 (en) * 2016-02-16 2017-08-24 Albert Einstein College Of Medicine, Inc. Dengue virus glycoprotein e diii variants and uses thereof
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
JP6518971B2 (en) * 2017-05-12 2019-05-29 株式会社ベックス Electroporator power supply
JP6795468B2 (en) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it
JP7075130B2 (en) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Human papillomavirus vaccine and how to use it

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
PT836482E (en) * 1995-05-24 2003-02-28 Hawaii Biotech Group SUBUNITARY VACCINE AGAINST FLAVIRUS INFECTION
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU4219399A (en) * 1998-06-08 1999-12-30 Valentis, Inc. Formulations for electroporation
CA2361601A1 (en) * 1999-02-08 2000-08-10 Cheryl Goldbeck Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
CA2425152A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
JP3543326B2 (en) 2001-08-30 2004-07-14 ソニー株式会社 Information processing apparatus and method, information processing system, information distribution apparatus, recording medium, and program
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
EP1573004A4 (en) 2002-11-04 2006-08-09 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
TWI303275B (en) 2003-05-30 2008-11-21 Advisys Inc Devices and methods for biomaterial production
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2007034507A2 (en) 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
CN105567672A (en) 2007-05-23 2016-05-11 Vgxi公司 Compositions comprising high concentration of biologically active molecules and processes for preparing the same
KR20140137679A (en) 2013-05-23 2014-12-03 삼성전자주식회사 Socket for card

Also Published As

Publication number Publication date
US8835620B2 (en) 2014-09-16
WO2009099716A1 (en) 2009-08-13
ES2685435T3 (en) 2018-10-09
KR101686942B1 (en) 2016-12-28
KR20100103677A (en) 2010-09-27
MX2010007461A (en) 2010-10-20
JP2011509659A (en) 2011-03-31
CA2708668A1 (en) 2009-08-13
WO2009099716A9 (en) 2009-10-01
EP2234624A4 (en) 2013-02-13
US20100291144A1 (en) 2010-11-18
ZA201004688B (en) 2011-04-28
CN101909635B (en) 2014-09-17
CN101909635A (en) 2010-12-08
EP2234624B1 (en) 2018-06-20
CA2708668C (en) 2019-03-05
AU2009210624A1 (en) 2009-08-13
JP5788676B2 (en) 2015-10-07
EP2234624A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
WO2009099716A4 (en) Novel vaccines against multiple subtypes of dengue virus
JP6549194B2 (en) Novel vaccine against multiple subtypes of influenza virus
JP7142427B2 (en) Consensus prostate antigen, nucleic acid molecules encoding same, and vaccines and uses containing same
JP5992337B2 (en) Influenza nucleic acid molecules and vaccines made therefrom
JP5763541B2 (en) Antigen causing immune response to flavivirus and method of use thereof
JP7317017B2 (en) Hepatitis B virus (HBV) vaccine and its use
WO2011054011A4 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
JP2016517414A (en) Influenza nucleic acid molecules and vaccines made therefrom
CN104673802A (en) Irisin protein encoded nucleic acid molecule and method utilizing nucleic acid molecule to efficiently express irisin protein
EP3662935A1 (en) Cross-protective arenavirus vaccines and their method of use
JP7123800B2 (en) Cancer vaccine and method of treatment therewith
US20210401970A1 (en) Canine distemper vaccines and methods of treatment using the same
Andrew et al. Porcine interleukin-3 enhances DNA vaccination against classical swine fever
US20210401965A1 (en) A novel dna vaccine against crimean-congo hemorrhagic fever virus (cchfv)
US11596678B2 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2019516741A (en) Synthetic malaria immunogens, combinations thereof and their use for preventing and treating malarial infections
CA2702971C (en) Antibody production elicited by a dna vaccine delivered by electroporation
CN101168064B (en) Recombination human pancreatic cancer mucus protein core peptide DNA vaccine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980101862.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09707528

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2708668

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009210624

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4529/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/007461

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009210624

Country of ref document: AU

Date of ref document: 20090112

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010542412

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009707528

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12812268

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20107017763

Country of ref document: KR

Kind code of ref document: A